338TiP CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer von Hamilton, E., Schiavon, G., Grinsted, L.M., De Bruin, E.C., Catanese, M.T., Rugo, H.S.

Volltext

101 HUMAN MONOCLONAL ANTIBODIES TARGETING SR-BI PREVENT HCV ENTRY AND VIRAL SPREAD IN VIVO von Meuleman, P, Catanese, M.T, Verhoye, L, Desombere, I, Jones, C.T, Walter, H, Grzyb, K, Cortese, R, Rice, C.M, Leroux-Roels, G, Nicosia, A

Volltext